Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822430 | 0.89 | PARP1 (0.63) | PARP1PARP2 | |
| SCHEMBL30418206 | 0.89 | PARP1 (0.63) | PARP1PARP2 | |
| SCHEMBL30418027 | 0.89 | PARP1 (0.61) | PARP1PARP2 | |
| SCHEMBL12821925 | 0.89 | PARP1 (0.61) | PARP1PARP2 | |
| SCHEMBL15420996 | 0.88 | CNR2 (0.54) | PARP1PARP2 | |
| SCHEMBL30427399 | 0.88 | PARP1 (0.57) | PARP1PARP2 | |
| SCHEMBL12822250 | 0.88 | PARP1 (0.57) | PARP1PARP2 | |
| Hydrochloric Acid SCHEMBL15420661 | 0.88 | PARP1 (0.61) | PARP1PARP2 | |
| SCHEMBL15420899 | 0.86 | CNR2 (0.56) | PARP1PARP2 | |
| SCHEMBL12700108 | 0.85 | PARP1 (0.71) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263801-A1 | COMBINATION THERAPY OF PARP INHIBITORS | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-24 | — | — | US | claimed |
| EP-2709990-B1 | 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer | IMPACT THERAPEUTICS INC (CN) | 2019-06-12 | — | — | EP | claimed |
| US-20140023642-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2014-01-23 | — | — | US | claimed |
| US-20230263801-A1 | COMBINATION THERAPY OF PARP INHIBITORS | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-24 | — | — | US | disclosed |
| US-11358955-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20190270732-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-2709990-B1 | 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer | IMPACT THERAPEUTICS INC (CN) | 2019-06-12 | — | — | EP | disclosed |
| US-10316027-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2019-06-11 | — | — | US | disclosed |
| US-20180215741-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS INC (CN) | 2018-08-02 | — | — | US | disclosed |
| US-9926304-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-20160237070-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-9290460-B2 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| US-20140023642-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270732-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | PARP1 1/4885PARP2 5/4885 |
| US-20230263801-A1 | COMBINATION THERAPY OF PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885 |
| US-10316027-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | PARP1, PARP11, PARP3 | PARP1 1/4885PARP2 4/4885 |
| US-20160237070-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | PARP1 1/4885PARP2 5/4885 |
| US-20180215741-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | PARP1 1/4885PARP2 4/4885 |
| US-11358955-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | PARP1, PARP11, PARP3 | PARP1 1/4885PARP2 5/4885 |
| US-20140023642-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | PARP1 1/4885PARP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.